These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7598728)

  • 1. Enhancement of damage-specific DNA binding of XPA by interaction with the ERCC1 DNA repair protein.
    Nagai A; Saijo M; Kuraoka I; Matsuda T; Kodo N; Nakatsu Y; Mimaki T; Mino M; Biggerstaff M; Wood RD
    Biochem Biophys Res Commun; 1995 Jun; 211(3):960-6. PubMed ID: 7598728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential binding of DNA repair proteins RPA and ERCC1 to XPA in vitro.
    Saijo M; Kuraoka I; Masutani C; Hanaoka F; Tanaka K
    Nucleic Acids Res; 1996 Dec; 24(23):4719-24. PubMed ID: 8972858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in XPA that prevent association with ERCC1 are defective in nucleotide excision repair.
    Li L; Peterson CA; Lu X; Legerski RJ
    Mol Cell Biol; 1995 Apr; 15(4):1993-8. PubMed ID: 7891694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific association between the human DNA repair proteins XPA and ERCC1.
    Li L; Elledge SJ; Peterson CA; Bales ES; Legerski RJ
    Proc Natl Acad Sci U S A; 1994 May; 91(11):5012-6. PubMed ID: 8197174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell cycle checkpoint abrogator UCN-01 inhibits DNA repair: association with attenuation of the interaction of XPA and ERCC1 nucleotide excision repair proteins.
    Jiang H; Yang LY
    Cancer Res; 1999 Sep; 59(18):4529-34. PubMed ID: 10493501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.
    Gentile F; Tuszynski JA; Barakat KH
    J Mol Graph Model; 2016 Apr; 65():71-82. PubMed ID: 26939044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways.
    Orelli B; McClendon TB; Tsodikov OV; Ellenberger T; Niedernhofer LJ; Schärer OD
    J Biol Chem; 2010 Feb; 285(6):3705-3712. PubMed ID: 19940136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical analysis of the damage recognition process in nucleotide excision repair.
    You JS; Wang M; Lee SH
    J Biol Chem; 2003 Feb; 278(9):7476-85. PubMed ID: 12486030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of nucleotide excision repair by anti-XPA monoclonal antibodies which interfere with binding to RPA, ERCC1, and TFIIH.
    Saijo M; Matsuda T; Kuraoka I; Tanaka K
    Biochem Biophys Res Commun; 2004 Sep; 321(4):815-22. PubMed ID: 15358100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA repair gets physical: mapping an XPA-binding site on ERCC1.
    Croteau DL; Peng Y; Van Houten B
    DNA Repair (Amst); 2008 May; 7(5):819-26. PubMed ID: 18343204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formation of a ternary complex by human XPA, ERCC1, and ERCC4(XPF) excision repair proteins.
    Park CH; Sancar A
    Proc Natl Acad Sci U S A; 1994 May; 91(11):5017-21. PubMed ID: 8197175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a damaged-DNA binding domain of the XPA protein.
    Kuraoka I; Morita EH; Saijo M; Matsuda T; Morikawa K; Shirakawa M; Tanaka K
    Mutat Res; 1996 Jan; 362(1):87-95. PubMed ID: 8538652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.
    Lan L; Hayashi T; Rabeya RM; Nakajima S; Kanno Si; Takao M; Matsunaga T; Yoshino M; Ichikawa M; Riele Ht; Tsuchiya S; Tanaka K; Yasui A
    DNA Repair (Amst); 2004 Feb; 3(2):135-43. PubMed ID: 14706347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small Molecule Antagonists of the DNA Repair ERCC1/XPA Protein-Protein Interaction.
    Obermann R; Yemane B; Jarvis C; Franco FM; Kyriukha Y; Nolan W; Gohara B; Krezel AM; Wildman SA; Janetka JW
    ChemMedChem; 2024 Apr; 19(8):e202300648. PubMed ID: 38300970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational determinants for the recruitment of ERCC1 by XPA in the nucleotide excision repair (NER) Pathway: structure and dynamics of the XPA binding motif.
    Fadda E
    Biophys J; 2013 Jun; 104(11):2503-11. PubMed ID: 23746523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TGF beta promotes repair of bulky DNA damage through increased ERCC1/XPF and ERCC1/XPA interaction.
    Zheng H; Jarvis IWH; Bottai M; Dreij K; Stenius U
    Carcinogenesis; 2019 Jun; 40(4):580-591. PubMed ID: 30418489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA.
    Tsodikov OV; Ivanov D; Orelli B; Staresincic L; Shoshani I; Oberman R; Schärer OD; Wagner G; Ellenberger T
    EMBO J; 2007 Nov; 26(22):4768-76. PubMed ID: 17948053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Domains in the XPA protein important in its role as a processivity factor.
    Bartels CL; Lambert MW
    Biochem Biophys Res Commun; 2007 Apr; 356(1):219-25. PubMed ID: 17349973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xeroderma pigmentosum complementation group A protein acts as a processivity factor.
    Lambert MW; Yang L
    Biochem Biophys Res Commun; 2000 May; 271(3):782-7. PubMed ID: 10814539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A truncated human xeroderma pigmentosum complementation group A protein expressed from an adenovirus sensitizes human tumor cells to ultraviolet light and cisplatin.
    Rosenberg E; Taher MM; Kuemmerle NB; Farnsworth J; Valerie K
    Cancer Res; 2001 Jan; 61(2):764-70. PubMed ID: 11212280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.